A multiphasic core-shell flurbiprofen and ciprofloxacin-loaded nanofibrous dressing cures infected burns via dual control of infection and inflammatory response.

Burn injury treatment is usually accompanied by significant challenges, such as microbial growth and chronic inflammation. A multifunctional nanofibrous dressing with biphasic chemical properties is fabricated to regulate infection and inflammation in infected burns simultaneously. Hydrophobic polymer polycaprolactone (PCL) and hydrophilic polymer chitosan (CS) were used to fabricate a core-shell nanofibrous dressing that encapsulates the anti-inflammatory drug flurbiprofen (FLB) and the antibacterial drug ciprofloxacin (CIP). The dressings PCL-CS/FLB-CIP were characterized using TEM, FESEM, contact angle measurements, and FTIR spectroscopy. The phase boundaries in the fibers result in controlled release of both drugs, i.e., 70 h and 80 h, CIP and FLB, respectively, in vitro. The dressings exhibited significant ROS scavenging activity and in vitro biocompatibility over NHDF cells, with good cell adhesion for up to 7 days. The in vitro antibacterial properties exhibited maximum inhibition at 50-60 h against Staphylococcus aureus and Escherichia coli. Furthermore, the effect of FLB release showed immunomodulatory efficacy of the dressings when determined against macrophage-like THP-1 cells. Furthermore, the in vivo healing potential of the dressings was determined over infected burns with Staphylococcus aureus in BALB/c mice and this group showed significant healing on day 18 compared to the untreated group. Bacterial growth inhibition, re-epithelization, neovascularization, collagen reappearance, and orientation were determined using the colony count method, and H&E, MT, and VG staining, respectively. Also, evidence from IHC staining confirmed secondary skin organ formation. The PCL-CS-based dual drug delivery system provides synergistic enhanced therapeutic efficacy and could be a solution to the simultaneous challenges in burn wounds.